Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is taking a stable daily dose of opioids of ≥30-mg morphine-equivalent total daily dose (METDD) for chronic non-cancer pain~* Has constipation that is caused by the chronic use of opioids~* Is willing to use only the study-provided laxative(s) and to discontinue use of all other laxatives, enemas, stool softeners, and other medications to treat constipation (for example, lubiprostone) during the study period (from Screening until the last study assessment).~* Is able and willing to refrain from facilitating defecation via manual maneuvers (for example, digital evacuation or support of the pelvic floor) during the study period (from Screening to the last study assessment)~Exclusion Criteria:~* Has gastrointestinal (GI) or pelvic disorders known to affect bowel transit (for example, obstruction) or contribute to bowel dysfunction~* Has evidence of intestinal obstruction~* Has a history of rectal bleeding not due to hemorrhoids or fissures~* Has an active malignancy of any type (participants with a history of successfully treated malignancy \>5 years before the scheduled administration of study medication and participants with treated basal or squamous cell cancer may be enrolled)~* Is taking antispasmodics (for example, dicyclomine), antidiarrheals (for example, loperamide), prokinetics (for example, metoclopramide), or locally acting chloride channel activators (for example, lubiprostone)~* Is taking non-opioid medications known to cause constipation (for example, iron sulfate therapy or tricyclic antidepressants)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CB-5945 (Type: EXPERIMENTAL): 0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, administered orally, BID for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).